Neurobiological announces U.S. Phase III Memantine data

NTII and partner Merz (Frankfurt, Germany) presented data from a double-blind, placebo-controlled U.S. Phase III trial in over 250 patients with moderate to severe Alzheimer's disease. Patients in the...